Of three key targets of miR-204-5p (BCL2, RAB22A and CREB1), BCL2 and RAB22A have been reported to promote tumor growth and drug resistance, demonstrating the functional similarity of UCA1 21, 35, 36. This evidence concerns the gene RAB22A and neoplasm.